Baidu
map

Ann Neurol:瑞金医院研究证明NMDA受体阻断剂改善MS

2014-01-20 丁燕敏 医学论坛网

瑞金医院神经内科研究团队与国外合作对于中枢神经系统低糖性白质损伤的研究成果于1月3日在神经病学最高影响力刊物Annals of Neurology在线发表。研究人员发现,在外周血糖低于正常范围时,中枢神经系统白质内精氨酸释放增多,激活神经纤维髓鞘少突胶质细胞膜上NMDA受体,导致神经纤维髓鞘脱失和神经传导受损。这也证明了在临床上反复发作性低血糖事件,如胰岛素瘤、或不当节食等,都可能导致不可

瑞金医院神经内科研究团队与国外合作对于中枢神经系统低糖性白质损伤的研究成果于1月3日在神经病学最高影响力刊物Annals of Neurology在线发表。研究人员发现,在外周血糖低于正常范围时,中枢神经系统白质内精氨酸释放增多,激活神经纤维髓鞘少突胶质细胞膜上NMDA受体,导致神经纤维髓鞘脱失和神经传导受损。这也证明了在临床上反复发作性低血糖事件,如胰岛素瘤、或不当节食等,都可能导致不可逆性中枢神经系统损伤,而阻断NMDA受体,可以有效地保护神经纤维完整性和神经传导功能。该研究成果受到国际同仁瞩目,国际神经病学权威专家Raymond A.Swanson教授为该研究成果撰写评论,并给予高度评价。【原文下载】

论文第一作者、瑞金医院神经内科青年医师杨欣进一步解释说,在很多累及中枢神经系统白质疾病如多发性硬化(MS)中可能同样存在能量缺乏而导致中枢神经纤维髓鞘损伤。MS多见于中青年女性,侵犯中枢神经系统最常见的部位为脊髓(61%),其次为大脑(55%)和视神经(41%)。患者会在短时间内四肢无力麻木,双眼视力急剧下降,疾病反复发作,迁延恶化致残,乃至死亡,给家庭和社会造成极大的负担,然而该疾病的致病机制仍不明确。

针对近年来MS的发病增加的趋势,瑞金医院神经内科组成专科医师、流行病学专家和实验人员的研究团队,通过建立全市MS协作网络,历经多年来的联合攻关,从分子、细胞和整体水平将基础研究与临床研究紧密结合,首报我国MS的患病率为1.39例/10万,白介素-6、17、18和23与MS的发病相关,并可能成为监测MS的生物标志物,曾先后发表于《神经病学》和《神经免疫学杂志》,对更好地认识及诊治MS提供了理论和实验依据。该研究团队的研究成果提示在MS急性发作期,早期采用NMDA受体阻断剂可能有助于改善MS患者的神经功能损伤。

原文出处:
Yang X1, Hamner M.A2, Brown A.M3, Evans R3, Ye Z2, Chen S.D1, Ransom B.R2.Novel hypoglycemic injury mechanism: NMDA receptor-mediated white matter damage.Ann Neurol. 2013 Nov 16. doi: 10.1002/ana.24050. 【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999366, encodeId=4d4b199936641, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Dec 27 02:46:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030208, encodeId=d6b6203020849, content=<a href='/topic/show?id=4a67128814c' target=_blank style='color:#2F92EE;'>#NMDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12881, encryptionId=4a67128814c, topicName=NMDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Fri Jan 02 16:46:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816416, encodeId=f786181641691, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun Jun 08 02:46:00 CST 2014, time=2014-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709983, encodeId=f0c61e09983e6, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu May 22 14:46:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943507, encodeId=31a9194350ebb, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Mar 30 20:46:00 CST 2014, time=2014-03-30, status=1, ipAttribution=)]
    2014-12-27 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999366, encodeId=4d4b199936641, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Dec 27 02:46:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030208, encodeId=d6b6203020849, content=<a href='/topic/show?id=4a67128814c' target=_blank style='color:#2F92EE;'>#NMDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12881, encryptionId=4a67128814c, topicName=NMDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Fri Jan 02 16:46:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816416, encodeId=f786181641691, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun Jun 08 02:46:00 CST 2014, time=2014-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709983, encodeId=f0c61e09983e6, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu May 22 14:46:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943507, encodeId=31a9194350ebb, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Mar 30 20:46:00 CST 2014, time=2014-03-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1999366, encodeId=4d4b199936641, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Dec 27 02:46:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030208, encodeId=d6b6203020849, content=<a href='/topic/show?id=4a67128814c' target=_blank style='color:#2F92EE;'>#NMDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12881, encryptionId=4a67128814c, topicName=NMDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Fri Jan 02 16:46:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816416, encodeId=f786181641691, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun Jun 08 02:46:00 CST 2014, time=2014-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709983, encodeId=f0c61e09983e6, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu May 22 14:46:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943507, encodeId=31a9194350ebb, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Mar 30 20:46:00 CST 2014, time=2014-03-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1999366, encodeId=4d4b199936641, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Dec 27 02:46:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030208, encodeId=d6b6203020849, content=<a href='/topic/show?id=4a67128814c' target=_blank style='color:#2F92EE;'>#NMDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12881, encryptionId=4a67128814c, topicName=NMDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Fri Jan 02 16:46:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816416, encodeId=f786181641691, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun Jun 08 02:46:00 CST 2014, time=2014-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709983, encodeId=f0c61e09983e6, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu May 22 14:46:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943507, encodeId=31a9194350ebb, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Mar 30 20:46:00 CST 2014, time=2014-03-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1999366, encodeId=4d4b199936641, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Dec 27 02:46:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030208, encodeId=d6b6203020849, content=<a href='/topic/show?id=4a67128814c' target=_blank style='color:#2F92EE;'>#NMDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12881, encryptionId=4a67128814c, topicName=NMDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Fri Jan 02 16:46:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816416, encodeId=f786181641691, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun Jun 08 02:46:00 CST 2014, time=2014-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709983, encodeId=f0c61e09983e6, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Thu May 22 14:46:00 CST 2014, time=2014-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943507, encodeId=31a9194350ebb, content=<a href='/topic/show?id=daad11404a3' target=_blank style='color:#2F92EE;'>#MDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11404, encryptionId=daad11404a3, topicName=MDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sun Mar 30 20:46:00 CST 2014, time=2014-03-30, status=1, ipAttribution=)]
    2014-03-30 wetgdt

相关资讯

Diabetes Care:瑞金医院沈卫峰发现ApoA–I糖基化水平与CAD严重程度有关

为了探讨在2型糖尿病患者,脱辅基蛋白(apo)A–I糖基化水平是否与冠状动脉疾病(CAD)和斑块进展有关,来自上海交通大学附属瑞金医院心内科的沈卫峰教授及其团队进行了一项研究(Glycation of apoprotein a-I is associated with coronary artery plaque progression in type 2 diabetic patients),该

Baidu
map
Baidu
map
Baidu
map